| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 17 | 2024 | 982 | 3.020 |
Why?
|
| Neurology | 10 | 2016 | 74 | 1.950 |
Why?
|
| Ischemic Attack, Transient | 6 | 2023 | 182 | 1.930 |
Why?
|
| Receptors, AMPA | 11 | 2009 | 66 | 1.480 |
Why?
|
| Clinical Clerkship | 8 | 2016 | 118 | 1.470 |
Why?
|
| Brain Ischemia | 6 | 2023 | 399 | 1.150 |
Why?
|
| Calcium | 16 | 2007 | 1172 | 1.140 |
Why?
|
| Cerebral Small Vessel Diseases | 2 | 2024 | 9 | 1.070 |
Why?
|
| Neurons | 19 | 2011 | 1580 | 1.040 |
Why?
|
| Clinical Competence | 4 | 2015 | 780 | 0.800 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2023 | 109 | 0.790 |
Why?
|
| Glutamic Acid | 8 | 2007 | 154 | 0.780 |
Why?
|
| Students, Medical | 4 | 2015 | 418 | 0.760 |
Why?
|
| Education, Medical, Undergraduate | 4 | 2016 | 178 | 0.750 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2023 | 143 | 0.740 |
Why?
|
| Foramen Ovale, Patent | 1 | 2021 | 18 | 0.740 |
Why?
|
| Nonlinear Dynamics | 1 | 2021 | 73 | 0.740 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 350 | 0.690 |
Why?
|
| Neurologic Examination | 2 | 2020 | 120 | 0.680 |
Why?
|
| Motor Neurons | 4 | 2001 | 174 | 0.670 |
Why?
|
| Stroke, Lacunar | 2 | 2018 | 4 | 0.660 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 376 | 0.620 |
Why?
|
| Reperfusion Injury | 2 | 2011 | 140 | 0.610 |
Why?
|
| Hypertension | 1 | 2024 | 741 | 0.610 |
Why?
|
| Intracranial Embolism | 1 | 2018 | 29 | 0.590 |
Why?
|
| Brain | 5 | 2024 | 2281 | 0.590 |
Why?
|
| Aspirin | 4 | 2023 | 159 | 0.560 |
Why?
|
| Kainic Acid | 8 | 2001 | 22 | 0.550 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 146 | 0.540 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 271 | 0.540 |
Why?
|
| Purkinje Cells | 6 | 1999 | 84 | 0.520 |
Why?
|
| Patient Simulation | 1 | 2015 | 42 | 0.510 |
Why?
|
| Statistics as Topic | 2 | 2015 | 234 | 0.510 |
Why?
|
| Heart Diseases | 1 | 2018 | 298 | 0.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1176 | 0.500 |
Why?
|
| Cells, Cultured | 21 | 2014 | 2880 | 0.500 |
Why?
|
| Cerebral Cortex | 3 | 2011 | 589 | 0.500 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2014 | 155 | 0.470 |
Why?
|
| Inpatients | 4 | 2023 | 310 | 0.460 |
Why?
|
| Intracranial Hemorrhages | 5 | 2023 | 129 | 0.460 |
Why?
|
| Nerve Degeneration | 4 | 2011 | 83 | 0.450 |
Why?
|
| Patch-Clamp Techniques | 9 | 2011 | 396 | 0.450 |
Why?
|
| Nitric Oxide | 4 | 2011 | 279 | 0.430 |
Why?
|
| Rats | 21 | 2007 | 4040 | 0.420 |
Why?
|
| Pyramidal Cells | 3 | 2007 | 81 | 0.420 |
Why?
|
| Echocardiography | 1 | 2018 | 937 | 0.420 |
Why?
|
| Tunicamycin | 1 | 2012 | 13 | 0.410 |
Why?
|
| Cerebellum | 7 | 2014 | 249 | 0.410 |
Why?
|
| Inclusion Bodies | 1 | 2012 | 34 | 0.410 |
Why?
|
| Ammonia | 1 | 2011 | 38 | 0.400 |
Why?
|
| Hyperammonemia | 1 | 2011 | 13 | 0.400 |
Why?
|
| Hepatic Encephalopathy | 1 | 2011 | 39 | 0.390 |
Why?
|
| Brain Edema | 1 | 2011 | 58 | 0.380 |
Why?
|
| Recurrence | 5 | 2022 | 1140 | 0.370 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 783 | 0.370 |
Why?
|
| Spinal Cord | 3 | 2001 | 255 | 0.370 |
Why?
|
| Humans | 37 | 2024 | 89063 | 0.360 |
Why?
|
| Educational Measurement | 1 | 2012 | 231 | 0.360 |
Why?
|
| Thrombectomy | 5 | 2024 | 172 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2007 | 1237 | 0.340 |
Why?
|
| Receptors, Glutamate | 3 | 2007 | 24 | 0.340 |
Why?
|
| Risk Factors | 7 | 2024 | 5466 | 0.330 |
Why?
|
| Animals | 32 | 2014 | 27317 | 0.310 |
Why?
|
| Cell Survival | 7 | 2011 | 982 | 0.310 |
Why?
|
| S-Nitrosothiols | 2 | 1997 | 5 | 0.300 |
Why?
|
| Hypoxia | 2 | 2011 | 650 | 0.290 |
Why?
|
| Intracranial Thrombosis | 2 | 2020 | 27 | 0.290 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1241 | 0.290 |
Why?
|
| Endovascular Procedures | 2 | 2023 | 270 | 0.290 |
Why?
|
| Hippocampus | 4 | 1999 | 447 | 0.280 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2007 | 52 | 0.280 |
Why?
|
| Organ Culture Techniques | 3 | 2012 | 135 | 0.270 |
Why?
|
| Fluorescent Dyes | 2 | 2004 | 243 | 0.260 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 6 | 2008 | 87 | 0.260 |
Why?
|
| Ambulatory Care Facilities | 2 | 2016 | 111 | 0.250 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 521 | 0.250 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2000 | 10 | 0.250 |
Why?
|
| Cell Hypoxia | 1 | 2005 | 170 | 0.240 |
Why?
|
| Pyramidal Tracts | 1 | 2004 | 17 | 0.240 |
Why?
|
| Motor Cortex | 1 | 2007 | 199 | 0.240 |
Why?
|
| Animals, Newborn | 4 | 2012 | 524 | 0.240 |
Why?
|
| Staining and Labeling | 1 | 2004 | 168 | 0.230 |
Why?
|
| Glucose | 2 | 2022 | 630 | 0.220 |
Why?
|
| Calcium Channels | 3 | 2001 | 182 | 0.220 |
Why?
|
| Thrombolytic Therapy | 3 | 2023 | 232 | 0.220 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 72 | 0.220 |
Why?
|
| Blotting, Western | 4 | 2014 | 794 | 0.220 |
Why?
|
| Basilar Artery | 3 | 2023 | 42 | 0.220 |
Why?
|
| Retrospective Studies | 10 | 2024 | 9003 | 0.220 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1715 | 0.210 |
Why?
|
| Cardiac Catheterization | 2 | 2021 | 302 | 0.210 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2001 | 187 | 0.210 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2023 | 55 | 0.210 |
Why?
|
| Treatment Outcome | 9 | 2024 | 8203 | 0.210 |
Why?
|
| Mice | 11 | 2014 | 11737 | 0.210 |
Why?
|
| Embolization, Therapeutic | 2 | 2024 | 262 | 0.210 |
Why?
|
| Risk Assessment | 3 | 2024 | 2290 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 4 | 2012 | 3209 | 0.210 |
Why?
|
| Kinetics | 4 | 2021 | 1528 | 0.200 |
Why?
|
| Time Factors | 8 | 2020 | 5320 | 0.200 |
Why?
|
| Chicago | 4 | 2020 | 1423 | 0.190 |
Why?
|
| Cell Death | 4 | 2007 | 262 | 0.190 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 44 | 0.180 |
Why?
|
| Calcium Signaling | 1 | 2001 | 138 | 0.180 |
Why?
|
| Homeostasis | 3 | 1997 | 413 | 0.180 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2752 | 0.180 |
Why?
|
| Cysteine | 2 | 1997 | 136 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2021 | 1714 | 0.170 |
Why?
|
| Secondary Prevention | 1 | 2020 | 158 | 0.170 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 98 | 0.170 |
Why?
|
| Excitatory Amino Acid Agonists | 3 | 2007 | 45 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 214 | 0.160 |
Why?
|
| Aged | 10 | 2024 | 19077 | 0.160 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 167 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 187 | 0.160 |
Why?
|
| Neural Inhibition | 1 | 1999 | 97 | 0.150 |
Why?
|
| Middle Aged | 11 | 2024 | 25863 | 0.150 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2017 | 18 | 0.150 |
Why?
|
| Prognosis | 4 | 2020 | 3773 | 0.150 |
Why?
|
| Male | 17 | 2024 | 42251 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 338 | 0.150 |
Why?
|
| N-Methylaspartate | 3 | 2007 | 51 | 0.150 |
Why?
|
| Independent Living | 1 | 2017 | 21 | 0.150 |
Why?
|
| Neurotoxins | 3 | 2007 | 49 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 833 | 0.140 |
Why?
|
| Receptors, Kainic Acid | 2 | 1994 | 13 | 0.140 |
Why?
|
| Neurosciences | 2 | 2015 | 52 | 0.140 |
Why?
|
| Female | 16 | 2024 | 46011 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 1999 | 277 | 0.140 |
Why?
|
| Membrane Potentials | 5 | 2000 | 436 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 887 | 0.130 |
Why?
|
| Hemolysis | 1 | 1995 | 64 | 0.130 |
Why?
|
| Embryo, Mammalian | 4 | 2010 | 221 | 0.130 |
Why?
|
| Intracellular Membranes | 2 | 1995 | 117 | 0.130 |
Why?
|
| Receptors, Neurotransmitter | 2 | 1992 | 26 | 0.130 |
Why?
|
| Cytosol | 1 | 1995 | 193 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 302 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.130 |
Why?
|
| Mitochondria | 1 | 1999 | 553 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1157 | 0.120 |
Why?
|
| Calpain | 1 | 1995 | 113 | 0.120 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1995 | 241 | 0.120 |
Why?
|
| Paresthesia | 1 | 2014 | 16 | 0.120 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 23 | 0.120 |
Why?
|
| Dizziness | 1 | 2014 | 26 | 0.120 |
Why?
|
| Specialty Boards | 1 | 2014 | 24 | 0.120 |
Why?
|
| Ataxia | 1 | 2014 | 39 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2011 | 901 | 0.110 |
Why?
|
| Hypoxia, Brain | 1 | 2014 | 43 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 120 | 0.110 |
Why?
|
| Amyloid beta-Peptides | 1 | 1995 | 212 | 0.110 |
Why?
|
| Workload | 1 | 2014 | 129 | 0.110 |
Why?
|
| RNA, Messenger | 5 | 2010 | 2011 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 1995 | 463 | 0.110 |
Why?
|
| Research | 1 | 2014 | 252 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 213 | 0.110 |
Why?
|
| Education, Medical | 1 | 2016 | 243 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2014 | 261 | 0.110 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2003 | 67 | 0.100 |
Why?
|
| Ibotenic Acid | 1 | 1992 | 5 | 0.100 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2012 | 8 | 0.100 |
Why?
|
| Protein Biosynthesis | 1 | 2014 | 388 | 0.100 |
Why?
|
| Cell Membrane Permeability | 2 | 2004 | 120 | 0.100 |
Why?
|
| Protein Isoforms | 2 | 2004 | 274 | 0.100 |
Why?
|
| Neuroprotective Agents | 2 | 2007 | 100 | 0.100 |
Why?
|
| Electrophysiology | 3 | 2007 | 403 | 0.100 |
Why?
|
| Disease Management | 1 | 2013 | 329 | 0.100 |
Why?
|
| Curriculum | 1 | 2016 | 567 | 0.100 |
Why?
|
| Nerve Net | 1 | 1995 | 372 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2001 | 79 | 0.090 |
Why?
|
| Magnesium | 1 | 1991 | 178 | 0.090 |
Why?
|
| Posterior Horn Cells | 2 | 2000 | 8 | 0.090 |
Why?
|
| Encephalitis | 1 | 2011 | 104 | 0.090 |
Why?
|
| Protein Transport | 1 | 2012 | 421 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2014 | 681 | 0.090 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2010 | 11 | 0.090 |
Why?
|
| Complement C5a | 1 | 2010 | 24 | 0.090 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2010 | 21 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2010 | 122 | 0.090 |
Why?
|
| Receptors, Complement | 1 | 2009 | 46 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 643 | 0.080 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 51 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2004 | 428 | 0.080 |
Why?
|
| Synaptic Transmission | 2 | 2004 | 228 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 1796 | 0.080 |
Why?
|
| Osmolar Concentration | 3 | 1997 | 181 | 0.080 |
Why?
|
| Gene Expression | 2 | 2004 | 1310 | 0.070 |
Why?
|
| Acidosis, Respiratory | 1 | 2007 | 7 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2009 | 210 | 0.070 |
Why?
|
| Motor Skills | 1 | 2008 | 79 | 0.070 |
Why?
|
| Hypercapnia | 1 | 2007 | 44 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 2362 | 0.070 |
Why?
|
| Apoptosis | 3 | 2010 | 1716 | 0.070 |
Why?
|
| Riluzole | 1 | 2007 | 15 | 0.070 |
Why?
|
| Malonates | 1 | 2007 | 11 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2010 | 727 | 0.070 |
Why?
|
| Sepsis | 1 | 2011 | 319 | 0.070 |
Why?
|
| Necrosis | 1 | 2007 | 209 | 0.070 |
Why?
|
| Dimerization | 2 | 2004 | 143 | 0.070 |
Why?
|
| Dipeptides | 2 | 1997 | 42 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 786 | 0.070 |
Why?
|
| Potassium | 1 | 2007 | 253 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 921 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2007 | 354 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2007 | 195 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 421 | 0.070 |
Why?
|
| Rats, Inbred Strains | 2 | 1997 | 312 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 103 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 207 | 0.060 |
Why?
|
| Enzymes | 1 | 1985 | 47 | 0.060 |
Why?
|
| Cell Line | 2 | 2014 | 2495 | 0.060 |
Why?
|
| Axonal Transport | 1 | 2004 | 31 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 243 | 0.060 |
Why?
|
| Benzoates | 1 | 2004 | 33 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 184 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2007 | 668 | 0.060 |
Why?
|
| Radial Artery | 1 | 2024 | 33 | 0.060 |
Why?
|
| Adult | 6 | 2024 | 26507 | 0.060 |
Why?
|
| Stochastic Processes | 1 | 2004 | 77 | 0.060 |
Why?
|
| Embolism | 1 | 2003 | 32 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2004 | 111 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 283 | 0.060 |
Why?
|
| Catheters | 1 | 2024 | 76 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2004 | 352 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 412 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 996 | 0.050 |
Why?
|
| Embolism, Paradoxical | 1 | 2002 | 2 | 0.050 |
Why?
|
| Transfection | 1 | 2004 | 911 | 0.050 |
Why?
|
| Fluorometry | 3 | 1997 | 30 | 0.050 |
Why?
|
| Education, Medical, Graduate | 2 | 2016 | 390 | 0.050 |
Why?
|
| Dizocilpine Maleate | 1 | 2001 | 12 | 0.050 |
Why?
|
| Lanthanum | 1 | 2001 | 16 | 0.050 |
Why?
|
| Cell Compartmentation | 1 | 2001 | 69 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2002 | 113 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 6777 | 0.050 |
Why?
|
| Benzothiadiazines | 1 | 2000 | 13 | 0.050 |
Why?
|
| Action Potentials | 1 | 2004 | 596 | 0.050 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2000 | 16 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 277 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2000 | 67 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2000 | 173 | 0.040 |
Why?
|
| Incidence | 2 | 2020 | 1592 | 0.040 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2010 | 36 | 0.040 |
Why?
|
| Fetus | 1 | 2001 | 232 | 0.040 |
Why?
|
| Astrocytes | 1 | 2000 | 141 | 0.040 |
Why?
|
| Hematoma | 1 | 2020 | 108 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2010 | 87 | 0.040 |
Why?
|
| Restriction Mapping | 1 | 1999 | 156 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 2019 | 14 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 70 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1867 | 0.040 |
Why?
|
| Kidney | 1 | 2004 | 1145 | 0.040 |
Why?
|
| Adolescent | 3 | 2023 | 9237 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 195 | 0.040 |
Why?
|
| Calcium Channel Blockers | 2 | 1995 | 121 | 0.040 |
Why?
|
| Glycolysis | 1 | 1999 | 135 | 0.040 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 1 | 1997 | 1 | 0.040 |
Why?
|
| Molsidomine | 1 | 1997 | 6 | 0.040 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 1997 | 11 | 0.040 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1997 | 14 | 0.040 |
Why?
|
| Penicillamine | 1 | 1997 | 12 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2000 | 364 | 0.040 |
Why?
|
| Ecuador | 1 | 2017 | 6 | 0.040 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1997 | 53 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 1999 | 316 | 0.040 |
Why?
|
| Rural Health | 1 | 2017 | 21 | 0.040 |
Why?
|
| Leukoencephalopathies | 1 | 2017 | 16 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 55 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 280 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 1997 | 59 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 779 | 0.040 |
Why?
|
| Ganglia, Spinal | 3 | 1994 | 75 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1063 | 0.040 |
Why?
|
| Hemoglobins | 1 | 1997 | 192 | 0.040 |
Why?
|
| Models, Biological | 1 | 2004 | 1763 | 0.040 |
Why?
|
| Cerebral Angiography | 1 | 2017 | 197 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 1997 | 177 | 0.030 |
Why?
|
| Benzamides | 1 | 1997 | 237 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 948 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1940 | 0.030 |
Why?
|
| Models, Neurological | 1 | 1999 | 409 | 0.030 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 1995 | 4 | 0.030 |
Why?
|
| Pyridoxal Phosphate | 1 | 1995 | 12 | 0.030 |
Why?
|
| Diphosphoglyceric Acids | 1 | 1995 | 10 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1997 | 284 | 0.030 |
Why?
|
| Suramin | 1 | 1995 | 27 | 0.030 |
Why?
|
| Nitroarginine | 1 | 1995 | 16 | 0.030 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1995 | 9 | 0.030 |
Why?
|
| Spectrin | 1 | 1995 | 15 | 0.030 |
Why?
|
| Calbindins | 1 | 1995 | 19 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 726 | 0.030 |
Why?
|
| Leucine | 1 | 1995 | 60 | 0.030 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 1995 | 22 | 0.030 |
Why?
|
| Nucleotides | 1 | 1995 | 97 | 0.030 |
Why?
|
| Carbachol | 1 | 1995 | 36 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2016 | 187 | 0.030 |
Why?
|
| Arginine | 1 | 1995 | 138 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2010 | 3373 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 126 | 0.030 |
Why?
|
| Sympathetic Nervous System | 1 | 1995 | 94 | 0.030 |
Why?
|
| Capsaicin | 2 | 1993 | 45 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 645 | 0.030 |
Why?
|
| Cycloleucine | 1 | 1994 | 10 | 0.030 |
Why?
|
| RNA Cap Analogs | 1 | 2014 | 2 | 0.030 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2014 | 8 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 771 | 0.030 |
Why?
|
| Vertebral Artery | 1 | 2014 | 24 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2014 | 35 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2014 | 47 | 0.030 |
Why?
|
| Cycloheximide | 1 | 2014 | 56 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 1995 | 190 | 0.030 |
Why?
|
| Specialization | 1 | 2014 | 65 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1995 | 698 | 0.030 |
Why?
|
| Luciferases | 1 | 2014 | 128 | 0.030 |
Why?
|
| Neuroglia | 1 | 1994 | 105 | 0.030 |
Why?
|
| Glutamates | 1 | 1994 | 89 | 0.030 |
Why?
|
| Career Choice | 1 | 2015 | 148 | 0.030 |
Why?
|
| China | 1 | 2014 | 233 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 599 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2014 | 159 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1240 | 0.030 |
Why?
|
| Plasmids | 1 | 2014 | 291 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2014 | 392 | 0.030 |
Why?
|
| Dendrites | 1 | 1993 | 102 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 375 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2000 | 1652 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 1995 | 511 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 313 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 557 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1706 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 1975 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1992 | 323 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1130 | 0.020 |
Why?
|
| Biological Transport | 1 | 1992 | 401 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 401 | 0.020 |
Why?
|
| Caffeine | 1 | 1991 | 83 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 2011 | 83 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 74 | 0.020 |
Why?
|
| Chemokine CXCL2 | 1 | 2010 | 16 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2010 | 20 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 108 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 153 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 73 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 35 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1591 | 0.020 |
Why?
|
| Complement Activation | 1 | 2009 | 81 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 167 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1990 | 0.020 |
Why?
|
| Seizures | 1 | 1991 | 306 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 1990 | 325 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 451 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 802 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 699 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2612 | 0.020 |
Why?
|
| Memory | 1 | 2008 | 220 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2006 | 140 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2015 | 1041 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2008 | 193 | 0.020 |
Why?
|
| Motor Activity | 1 | 2008 | 327 | 0.020 |
Why?
|
| Solvents | 1 | 1985 | 96 | 0.020 |
Why?
|
| Learning | 1 | 2008 | 285 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1985 | 289 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 1574 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2657 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 1533 | 0.010 |
Why?
|
| Binding Sites | 1 | 1985 | 1117 | 0.010 |
Why?
|
| United States | 2 | 2006 | 6955 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 1889 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 6288 | 0.010 |
Why?
|
| Warfarin | 1 | 2002 | 104 | 0.010 |
Why?
|
| Teratocarcinoma | 1 | 2000 | 1 | 0.010 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2000 | 8 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 56 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 55 | 0.010 |
Why?
|
| Lymphokines | 1 | 2000 | 76 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2000 | 115 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 130 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2000 | 43 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 418 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 291 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2000 | 342 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2000 | 188 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2000 | 170 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2002 | 426 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2000 | 814 | 0.010 |
Why?
|
| Stem Cells | 1 | 2000 | 372 | 0.010 |
Why?
|
| Protein Binding | 1 | 2000 | 1487 | 0.010 |
Why?
|
| Muscarine | 1 | 1995 | 1 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 1205 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 3657 | 0.010 |
Why?
|
| Fura-2 | 1 | 1994 | 22 | 0.010 |
Why?
|
| Terpenes | 1 | 1994 | 17 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1994 | 29 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1994 | 55 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1994 | 59 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1994 | 177 | 0.010 |
Why?
|
| Nicotine | 1 | 1995 | 199 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 543 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1993 | 289 | 0.010 |
Why?
|
| Ruthenium Red | 1 | 1990 | 2 | 0.010 |
Why?
|
| Barium | 1 | 1990 | 31 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 2327 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3027 | 0.010 |
Why?
|